For data and research buyers such as biotech, pharma, CRO, academic, DeSci, payer, and other teams evaluating governed real-world evidence or data access.
From member-side data to evidence-buyer diligence.
Evidence buyers include biotech, pharma, CROs, academic researchers, DeSci groups, payers, and other teams evaluating governed real-world evidence. Start here before reviewing methodology, data quality, governance, or data-request scope.
The sequence buyers should inspect.
The loop is intentionally framed as a diligence path. Synthetic and proxy support help explain the product shape; production evidence still requires the appropriate human reviews.
Member-consented inputs
Protocol logs, lab panels, wearable context, and phenotype reports enter the review path with consent and use boundaries.
Normalized multimodal dataset
Inputs are organized into a structured RWE shape that can be reviewed for completeness, gaps, and cohort fit.
Synthetic-control analysis
The DS-CDT demo shows how synthetic controls, biomarker volatility, and de-identified assets can be represented in product code.
Governed partner request
Any production access remains scoped by DUA, consent audit, de-identification review, and partner-specific requirements.
What this helps a buyer evaluate.
These use cases are framed as review paths, not clinical, legal, regulatory, or production readiness claims.
Synthetic-control exploration
Review how matched comparator logic could support external-control discussions after cohort, governance, and validation questions are answered.
Signal review across protocols
Inspect how protocol logs, wearable windows, and lab panels can be organized for research questions without presenting synthetic data as clinical proof.
Data-pack scoping
Move from evidence fit to a scoped request that defines cohort needs, refresh cadence, review boundaries, and access constraints.
How the evidence method becomes buyer-reviewable.
Data buyers do not need a patent-attorney claim map first. They need to understand whether the LifePrint method is transparent enough to evaluate, scoped enough to govern, and practical enough to pilot against a real research question.
What a buyer needs before purchasing.
This step keeps the conversation commercial and analytical. Patent validity, legal claim coverage, and implementation evidence belong in a separate counsel-led diligence path.
Question fit
Does the cohort, protocol category, and observation window match the buyer's research question?
Field coverage
Are labs, wearable context, protocol timing, consent state, and missingness clear enough for analysis planning?
Comparator method
Can the buyer understand how a modeled baseline or synthetic comparator is built and where it remains proxy-supported?
Use boundary
Does the request fit de-identification review, consent scope, DUA limits, and permitted-use expectations?
A transparent comparator workflow.
A Dynamic Synthetic-Control Digital Twin is the proposed evidence workflow for comparing a member's active protocol context with a modeled baseline or matched comparator. For a buyer, the important question is not whether the acronym sounds advanced. The question is whether the assumptions, inputs, limitations, and access boundaries are reviewable.
Member-consented labs, wearables, protocol logs, and phenotype context enter the review loop.
Inputs are normalized into a longitudinal evidence record with clear synthetic/demo and governance labels.
The DS-CDT method compares active protocol context with a modeled untreated baseline or matched comparator.
Outputs are reviewed as buyer diligence material before any scoped data request, DUA, or pilot conversation.
The buyer packet should answer these first.
This page is not a patent-validity opinion, clinical proof, regulatory approval, or automatic data-access offer. It is the buyer-facing bridge between the evidence loop and data-quality review.
Can the inputs support useful analysis?
The data-quality page explains the inputs before a buyer evaluates governance. It separates contextual wearable trends, protocol logs, and lab anchors so the RWE story does not feel like an unsupported black box.
Wearable context
Wearable windows provide physiological context around labs and protocol events. They are treated as contextual signals, not standalone clinical conclusions.
- Sleep and recovery windows
- Resting heart-rate context
- Autonomic trend summaries
Protocol logs
User-recorded protocols give analysts the timing and intervention context needed to interpret longitudinal changes.
- Compound or blend naming
- Route and timing context
- Phenotype and symptom notes
Lab anchors
Lab panels anchor the evidence loop with discrete biomarker values that can be reviewed against wearable and protocol context.
- Cardiometabolic markers
- Endocrine and organ-function markers
- Inflammatory and hematology markers
Quality review comes before data access.
Partner evaluation should inspect coverage, freshness, missingness, consent scope, and de-identification requirements before any dataset is scoped. This page describes the input model; it does not claim clinical validation or production readiness.
Can this be accessed safely?
Governance is the trust step between data-quality review and a data-request scope. This page explains the boundaries a partner should expect before any production access is discussed.
De-identification review
Partner data access is scoped around de-identification review, export exclusions, and documented use boundaries before any dataset is shared.
Consent records
Research participation and partner-contact preferences are treated as explicit consent states, with review needed before commercial use.
Scoped access
Partner requests are evaluated by cohort specification, permitted use, aggregation needs, and whether row-level access is appropriate.
DUA-first workflow
Production requests move through a Data Use Agreement and review process before exports, refresh cadence, or analysis support are defined.
Audit posture
Security and compliance work should be reviewed under the current control posture and any applicable audit status before enterprise access.
No real lab ordering here
The DS-CDT demo uses mock routing and synthetic data. It does not create real lab orders or real partner exports.
What can a partner ask to evaluate?
Data packs are the request step after a buyer has reviewed the RWE mechanism, evidence methodology, data quality, and governance model. Final scope depends on cohort fit, consent, de-identification review, and a signed agreement.
GLP-1 RWE review pack
A scoped review of adherence, titration context, wearable windows, and lab trajectories for a GLP-1-related research question.
- Adherence timing
- Dose-escalation context
- Side-effect timing
- Body-composition context
- Biomarker trajectory
Peptide cohort review
Review protocol logs, blend decomposition, wearable windows, and biomarker panels for a peptide-related research question after compliance and use-case review.
Hormone trajectory review
Review symptom context, lab trajectories, and wearable windows for a hormone-related research question after consent and governance review.
Choose the conversation, then scope the data.
The commercial conversation should follow diligence. These categories keep the next step practical without implying that production access is automatic.
Pilot review
A narrow partner conversation to inspect cohort fit, data fields, governance needs, and analysis boundaries.
Standard data pack
A scoped request for a defined cohort, refresh pattern, schema needs, and permitted-use review.
Custom evidence build
A partner-specific diligence path for synthetic-control, protocol, or longitudinal analysis questions.
Request a scoped evidence review.
Tell us what your team is trying to learn. We will route the inquiry toward evidence buying, data access, provider network, or governance review.